



June 30, 2025

BSE Limited

The Listing Department
Phiroze Jeejeebhoy Towers
25th Floor, Dalal Street
Fort, Mumbai 400 001
Maharashtra, India

BSE Scrip Code: 544309

National Stock Exchange of India Limited

The Listing Department
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (East), Mumbai 400051
Maharashtra, India

NSE Symbol: IKS

Dear Sir/Ma'am,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") – Investment by subsidiary of the Company.

With reference to the captioned subject, we would like to inform you that the Board of Directors at its Meeting held on Monday, June 30, 2025, approved investment upto USD 17,000,000 by Inventurus Knowledge Solutions Inc, a subsidiary of the Company in IKS WWMG MSO LLC ("**Target Company**") by subscribing upto 17,000,000 Common Units of the Target Company, which will result in acquisition of 48.02% of the outstanding equity interests of the Target Company by Inventurus Knowledge Solutions Inc.

The details required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 on disclosure of material events/ information by listed entities, dated November 11, 2024, in respect of the aforesaid investment are enclosed herewith as **Annexure A**.

We request you to take this on record.

Thanking you.

Yours sincerely,

For Inventurus Knowledge Solutions Limited

Sameer Chavan

Company Secretary and Compliance Officer

Membership No. F7211

Encl: As above

M/s. Inventurus Knowledge Solutions Limited

801, Building No. 5 & 6, 8th Floor, Mindspace Business Park (SEZ), Thane - Belapur Road, Airoli, Navi Mumbai - 400 708,
Thane, Maharashtra, India. | Board: +91 22 3071 1100 | Fax: 91 22 6646 6879 | info@ikshealth.in | www.ikshealth.com

Annexure – A

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.:	<p>Name of the target entity: IKS WWMG MSO LLC, (“Target Company”)</p> <p>Turnover as per last audited financials: Not Applicable Target Company is yet to commence its business.</p>
2.	<p>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?</p> <p>If yes, nature of interest and details thereof and whether the same is done at "arms length":</p>	<p>No.</p> <p>After completion of the aforesaid investment by Inventurus Knowledge Solutions Inc, a subsidiary of the Company (“IKS Inc”), Target Company will become an associate company of IKS Inc.</p> <p>Except to the extent of shareholding of Promoter / Promoter Group in the Company, the Promoter / Promoter Group of the Company do not have any interest in the Target Company or in the aforesaid transaction.</p>
3.	Industry to which the entity being acquired belongs:	Providing management, consulting, administrative, and other support services to physician practices that provide or arrange for the provision of professional healthcare services.
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	<p>The group is investing in MSO to strategically elevate its market position from a Service provider to a transformation partner and drive future growth creating a sustainable physician aggregation model, enhancing the stickiness of our care enablement platform. This transaction represents a strategic investment by the group intended to strengthen its competitive positioning, expand its market influence, and support long-term growth objectives.</p> <p>Through this investment, the group aims to drive strategic transformation across its customer base in response to evolving dynamics within the healthcare sector. Concurrently, it will enable the group to ascend the value chain, thereby enhancing its differentiation from commoditized service providers.</p> <p>Additionally, the investment is expected to increase the integration and long-term adoption of IKS’s care enablement platform, further reinforcing customer engagement and platform stickiness.</p>

5	Brief details of any governmental or regulatory approvals required for the acquisition:	Not applicable
6.	Indicative time period for completion of the acquisition:	July 15, 2025
7.	Nature of consideration - whether cash consideration or share swap and details of the same:	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired:	USD 17,000,000/- (17,000,000 Common Units valued at USD 1 per Unit)
9.	Percentage of shareholding / control acquired and / or number of shares acquired.	Percentage of shareholding: 48.02 % of the outstanding equity interests No. of Shares: 17,000,000 Common Units
10.	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	The Target Company was incorporated on June 12, 2025 in the United States of America with the business objective of providing management, consulting, administrative, and other support services to physician practices that provide or arrange for the provision of professional healthcare services. Since the said Target Company is newly incorporated, information related to turnover is not applicable.